Devimistat efficacy
| Devimistat efficacy . | Cohort 1∗ . | Cohort 2 . | ||
|---|---|---|---|---|
| R/R-BL . | R/R-PBL . | R/R-HGBCL with rearrangements of MYC and BCL2 and/or BCL6 . | ||
| Devimistat and response . | Overall, n (%) . | Evaluable, n (%) . | Overall,† n (%) . | Overall,† n (%) . |
| No. of patients | 13 (100) | 9 (100) | 2 (100) | 9 (100) |
| Median no. of cycles of devimistat | 1 | 1 | 1.4 | 1 |
| Range of no. of cycles of devimistat | 0-11 | 0.8-11 | 0.8-2 | 1-9 |
| Median follow-up time (range), mo | 1 (0-47) | 1 (0-47) | 0.5 (0-1) | 2 (0-8) |
| Best response | ||||
| CRR | 2 (15) | 2 (22) | 0 | 0 |
| PR | 0 | 0 | 0 | 0 |
| SD | 0 | 0 | 0 | 2 (22) |
| PD | 11 (85) | 7 (78) | 2 (100) | 7 (78) |
| Not evaluable | 4 (31) | 0 | 0 | 0 |
| Duration of response | Ongoing | Ongoing | 0 | 0 |
| Devimistat efficacy . | Cohort 1∗ . | Cohort 2 . | ||
|---|---|---|---|---|
| R/R-BL . | R/R-PBL . | R/R-HGBCL with rearrangements of MYC and BCL2 and/or BCL6 . | ||
| Devimistat and response . | Overall, n (%) . | Evaluable, n (%) . | Overall,† n (%) . | Overall,† n (%) . |
| No. of patients | 13 (100) | 9 (100) | 2 (100) | 9 (100) |
| Median no. of cycles of devimistat | 1 | 1 | 1.4 | 1 |
| Range of no. of cycles of devimistat | 0-11 | 0.8-11 | 0.8-2 | 1-9 |
| Median follow-up time (range), mo | 1 (0-47) | 1 (0-47) | 0.5 (0-1) | 2 (0-8) |
| Best response | ||||
| CRR | 2 (15) | 2 (22) | 0 | 0 |
| PR | 0 | 0 | 0 | 0 |
| SD | 0 | 0 | 0 | 2 (22) |
| PD | 11 (85) | 7 (78) | 2 (100) | 7 (78) |
| Not evaluable | 4 (31) | 0 | 0 | 0 |
| Duration of response | Ongoing | Ongoing | 0 | 0 |